Bank Sa Swissquote Sells 72,630 Shares of Cytori Therapeutics Inc (CYTX) Stock
Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Bank Sa Swissquote sold 72,630 shares of Cytori Therapeutics stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $0.34, for a total value of $24,694.20. Following the transaction, the insider now directly owns 5,496,655 shares in the company, valued at $1,868,862.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Bank Sa Swissquote also recently made the following trade(s):
- On Tuesday, January 9th, Bank Sa Swissquote sold 100,000 shares of Cytori Therapeutics stock. The stock was sold at an average price of $0.38, for a total value of $38,000.00.
Cytori Therapeutics Inc (NASDAQ CYTX) traded down $0.02 during mid-day trading on Thursday, hitting $0.34. The stock had a trading volume of 1,726,300 shares, compared to its average volume of 3,182,186. Cytori Therapeutics Inc has a 1 year low of $0.22 and a 1 year high of $2.13. The company has a market cap of $11.94, a price-to-earnings ratio of -0.38 and a beta of 3.21.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Sabby Management LLC lifted its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 28.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,626,807 shares of the biotechnology company’s stock after acquiring an additional 355,504 shares during the period. Sabby Management LLC owned approximately 4.69% of Cytori Therapeutics worth $1,789,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 7.41% of the company’s stock.
CYTX has been the topic of several recent research reports. Maxim Group set a $5.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a report on Thursday, October 19th. Zacks Investment Research raised Cytori Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, B. Riley reissued a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.